Starget Pharma

Company Overview

Snapshot

Founded in July 2019 by Sigal Kalmanson Cusnir and Ronen Kalmanson, Starget Pharma operates with 11–50 employees. The company has raised $33.1 million across three funding rounds. In February 2026, Starget Pharma secured an $18 million Series A funding round, led by.

Business overview

Starget Pharma is a Health Tech & Life Sciences company focused on developing products for the diagnosis and targeted treatment of cancer using targeted radiotherapy. The company specializes in creating molecules that serve as vectors for selectively transferring imaging materials and treatments directly to tumor tissue. Operating within the Pharma & Medical Biotechnology sector, Starget Pharma utilizes its proprietary Backbone Dynamics peptide platform to develop precision peptide radioligand therapies, primarily targeting the SSTR-3 somatostatin receptor overexpressed in tumor cells.

Strategic signal

In February 2026, Starget Pharma secured an $18 million Series A funding round, led by. This significant investment, coupled with plans to commence advanced clinical trials and expand operations in the U.S., signals strong investor confidence in the company's AI-based discovery platform and its potential to deliver innovative radiotherapy drugs for cancer treatment. The funding will support the commencement of clinical trials in collaboration with MD Anderson Cancer Center and expand the company's development and manufacturing infrastructure, indicating a clear path toward commercialization and market penetration.

Company Intelligence Q&A

What was a significant recent achievement for Starget Pharma?

In May 2026, Starget Pharma was awarded as one of the.

What was the outcome of Starget Pharma's Series A funding round?

In February 2026, Starget Pharma completed an $18 million Series A funding round. The funding was led by Ilex Medical and Louisiana Growth Fund, and will support the advancement of its radioactive oncological treatment, including the commencement of clinical trials and expansion of development and manufacturing infrastructure.

What strategic collaboration did Starget Pharma announce in February 2026?

In February 2026, Starget Pharma announced a strategic collaboration with the Center for Molecular Imaging and Therapy (CMIT) in Louisiana. This partnership aims to enhance the development and manufacturing of targeted radiopharmaceuticals.

What investment did Starget Pharma receive in October 2024?

In October 2024, Starget Pharma received a $5.1 million investment from Cancer Focus Fund. This funding was allocated to conduct a Phase 1b clinical trial for its lead theranostic, DOTA-PTR-58.

When was Starget Pharma founded and by whom?

Starget Pharma was founded in July 2019 by Sigal Kalmanson Cusnir and Ronen Kalmanson.